Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.
For decades, one of the biggest challenges for manufacturing cell therapies has been sorting the cells. Many upcoming cell therapies are based on isolation of specific cell phenotypes, defined by flow cytometry on multiple fluorescent markers. Unlike traditional sorting, GMP sorting needs to be fast, scalable and reliable enough to process the large quantities of cells relevant to upcoming cell therapies. Additionally, GMP sorting needs to be sterile and biocompatible in order to process a medicinal product.
Conventional cell sorting techniques have not kept pace with progress in cell therapy; there is currently a large divide between commercial sorting technologies and cell therapy requirements. Several new technologies have been invented to close this gap, although many difficulties remain.
Cellular Highways was founded with the mission to make high-throughput, sterile, scalable GMP cell sorting a reality, based on the microfluidic VACS technology. The first product, Highway1, has now entered beta testing with partners, and we are able to reveal initial data.
Join Samson Rogers, CEO and Co-Founder of Cellular Highways, a TTP company, as he reviews the requirements of GMP cell sorting in comparison with existing techniques; as well as introducing Highway1, its underlying technology, and initial results from beta users.